Literature DB >> 19876652

A case of minimal change disease in a Fabry patient.

Yuri A Zarate1, Larry Patterson, Hong Yin, Robert J Hopkin.   

Abstract

Fabry disease is an X-linked lysosomal storage disorder caused by mutations of the GLA gene and deficiency in alpha-galactosidase A activity. Glycosphingolipids accumulation causes renal injury that manifests early during childhood as tubular dysfunction and later in adulthood as proteinuria and renal insufficiency. Nephrotic syndrome as the first evidence of Fabry-related kidney damage is rare. We report the case of a teenager with known Fabry disease and normal renal function who developed acute nephrotic syndrome. He was found to have typical glycosphingolipids accumulation with no other findings suggestive of alternative causes of nephrotic syndrome on kidney biopsy. After treatment with enzyme replacement therapy and oral steroids, he went into complete remission from nephrotic syndrome, a response that is atypical for Fabry disease patients who develop heavy proteinuria as a result of longstanding disease and chronic renal injury. The nephrotic syndrome in this patient appears to have developed secondary to minimal change disease. We recommend considering immunotherapy in addition to enzyme replacement therapy in those patients with confirmed Fabry disease and acute nephrotic syndrome with clinical and microscopic findings suggestive of minimal change disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19876652     DOI: 10.1007/s00467-009-1353-0

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  20 in total

Review 1.  Natural history and treatment of renal involvement in Fabry disease.

Authors:  Mary Branton; Raphael Schiffmann; Jeffrey B Kopp
Journal:  J Am Soc Nephrol       Date:  2002-06       Impact factor: 10.121

Review 2.  Minimal change disease: a review.

Authors:  Tapasi C Saha; Harmeet Singh
Journal:  South Med J       Date:  2006-11       Impact factor: 0.954

Review 3.  Childhood nephrotic syndrome: change in pattern and response to steroids.

Authors:  Ifeoma Anochie; Felicia Eke; Augustina Okpere
Journal:  J Natl Med Assoc       Date:  2006-12       Impact factor: 1.798

4.  Fabry disease: a morphologic study of 11 cases.

Authors:  Edgar G Fischer; Michael J Moore; Donna J Lager
Journal:  Mod Pathol       Date:  2006-06-23       Impact factor: 7.842

5.  Enzyme-replacement therapy with agalsidase alfa in children with Fabry disease.

Authors:  Markus Ries; Joe T R Clarke; Catharina Whybra; Margaret Timmons; Chevalia Robinson; Bradley L Schlaggar; Gregory Pastores; Y Howard Lien; Christoph Kampmann; Roscoe O Brady; Michael Beck; Raphael Schiffmann
Journal:  Pediatrics       Date:  2006-09       Impact factor: 7.124

6.  [Fabry nephropathy in a female with superposed IgA glomerulonephritis].

Authors:  A Pisani; A Sessa; M Sabbatini; M V Andreucci; C Fusco; M Balletta; B Cianciaruso
Journal:  G Ital Nefrol       Date:  2005 Jul-Aug

7.  Nephropathy in males and females with Fabry disease: cross-sectional description of patients before treatment with enzyme replacement therapy.

Authors:  Alberto Ortiz; João P Oliveira; Steven Waldek; David G Warnock; Bruno Cianciaruso; Christoph Wanner
Journal:  Nephrol Dial Transplant       Date:  2008-01-05       Impact factor: 5.992

8.  Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.

Authors:  Hindia Tahir; Leslie L Jackson; David G Warnock
Journal:  J Am Soc Nephrol       Date:  2007-07-26       Impact factor: 10.121

Review 9.  Fabry's disease.

Authors:  Yuri A Zarate; Robert J Hopkin
Journal:  Lancet       Date:  2008-10-18       Impact factor: 79.321

10.  Crescentic glomerulonephritis in a patient with heterozygous Fabry's disease.

Authors:  Kanako Shimazu; Yoshiyuki Tomiyoshi; Shigehisa Aoki; Takanobu Sakemi; Hajime Sugihara
Journal:  Nephron       Date:  2002-10       Impact factor: 2.847

View more
  5 in total

Review 1.  Recommendations for the diagnosis and management of Fabry disease in pediatric patients: a document from the Rare Diseases Committee of the Brazilian Society of Nephrology (Comdora-SBN).

Authors:  Maria Helena Vaisbich; Luís Gustavo Modelli de Andrade; Cassiano Augusto Braga Silva; Fellype de Carvalho Barreto
Journal:  J Bras Nefrol       Date:  2022 Apr-Jun

2.  Effectiveness of immunosuppressive therapy for nephrotic syndrome in a patient with late-onset Fabry disease: a case report and literature review.

Authors:  Hironobu Fujisawa; Yosuke Nakayama; Shoichiro Nakao; Ryo Yamamoto; Yuka Kurokawa; Nao Nakamura; Akiko Nagata; Takahiro Tsukimura; Tadayasu Togawa; Hitoshi Sakuraba; Kei Fukami
Journal:  BMC Nephrol       Date:  2019-12-17       Impact factor: 2.388

3.  Screening for Fabry Disease in Young Strokes in the Australian Stroke Clinical Registry (AuSCR).

Authors:  Alejandra Malavera; Dominique A Cadilhac; Vincent Thijs; Joyce Y Lim; Brenda Grabsch; Sibilah Breen; Stephen Jan; Craig S Anderson
Journal:  Front Neurol       Date:  2020-11-24       Impact factor: 4.003

4.  Initially Nondiagnosed Fabry's Disease when Electron Microscopy Is Lacking: The Continuing Story of Focal and Segmental Glomerulosclerosis.

Authors:  H Trimarchi; A Karl; M S Raña; M Forrester; V Pomeranz; F Lombi; A Iotti
Journal:  Case Rep Nephrol Urol       Date:  2013-05-04

5.  Sudden onset of nephrotic syndrome in an asymptomatic Fabry patient: a case report.

Authors:  Ruixiao Zhang; Zeqing Chen; Yanhua Lang; Shihong Shao; Yan Cai; Qingqing You; Yan Sun; Sai Wang; Xiaomeng Shi; Zhiying Liu; Wencong Guo; Yue Han; Leping Shao
Journal:  Ren Fail       Date:  2020-11       Impact factor: 2.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.